• First Patient enrolled in the SAKK Investigator-Initiated Phase 1b trial of Docetaxel Micellar in Advanced Prostate Cancer

XR-17 is Oasmia’s proprietary delivery platform

CEO corner

Get to learn more about Francois Martelet, our CEO

Oasmia Pharmaceutical published its interim report for the first quarter of 2021 on May 27, 2021, at 08.00 am CEST.

The Share

Oasmia and Elevar sign a global strategic partnership for the commercialization of Apealea®

Annual Report 2020